Tag: STRO-001
Antibody-drug Conjugates: Coming of Age
Antibody-based anti-cancer therapeutics have, over the last 30+ years garnered considerable success. Antibody-drug Conjugates (ADC) are included in this revolution of these novel, highly...
ASH 2020: Preclinical Models Identify CD74 as Potential Target for the...
Presentations during the virtual 62nd American Society of Hematology (ASH) Annual Meeting for the ongoing Phase 1 dose-escalation clinical trial with STRO-001, a CD74-targeted...
Annual World ADC – Best New Drug Developer 2020: Sutro Biopharma’s...
From liquid biopsies to precision medicine to immunology, the field of cancer treatment has experienced significant progress during the last decade. Although according to...
Sutro Presents Preliminary Results From Ongoing Phase I Study of STRO-001
California-based Sutro Biopharma has confirmed that the company will present preliminary results from the first 14 patients enrolled in the company's ongoing Phase I...
Sutro Confirms IND for Second Cell-Free ADC Targeting Anti-Folate Receptor-α for...
Sutro Biopharma confirmed that the U.S. Food and Drug Administration (FDA) has concluded their 30-day review of the Investigational New Drug (IND) application for...
A New Generation of Precisely Engineered CD74-Targeting ADCs Receive Orphan Drug...
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for STRO-001 for the treatment of multiple myeloma (MM).
In the United States,...
Sutro Partners with The Leukemia & Lymphoma Society to Develop STRO-001
Earlier today Sutro Biopharma, a clinical-stage drug discovery, development and manufacturing company, and The Leukemia & Lymphoma Society®, the world's largest voluntary health agency...
First Clinical Trial of STRO-001 Targeting CD74 to Treat Lymphoma and...
Researchers have begun dosing patients in its initial clinical trial of a new generation of precisely engineered - first-in-class - antibody-drug conjugate, or ADC,...
Sutro BioPharma and Celgene Refocus Immuno-Oncology Collaboration – Rapidly Advance Promising...
Earlier today Sutro Biopharma and Celgene confirmed that the companies decided to refocusing the 2014 immuno-oncology collaboration with on four programs that are advancing...
Data Confirms STRO-001 Eradicates B-Cell Hematologic Malignancies and Prolongs Survival
STRO-001, an antibody-drug conjugate or ADC targeting the CD74 cell surface protein in hematologic B-cell malignancies, being developed by Sutro Biopharma, has shown to...
